Document Detail


Secretion from submucosal salivary glands of the ferret in response to a cholinesterase inhibitor applied onto the oral mucosa.
MedLine Citation:
PMID:  12120709     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Parasympathomimetics or cholinesterase inhibitors taken orally may relieve dry-mouth symptoms, but this route of administration is often associated with adverse systemic reactions. In the present study, an animal model was worked out aimed at stimulating the submucosal glands and avoiding systemic effects. In the anesthetized ferret, saliva from the parotid, sublingual and submandibular glands was prevented from reaching the mouth. Vehicle or physostigmine was applied topically for 10 min on the buccal and labial mucosa on one side, while the other side served as a control. Fluid from each side was collected every 5 min Mean basal secretion was 0.17 mg 5 min(-1). The response to physostigmine 0.1% did not exceed that of the vehicle. At higher concentrations the responses lasted 80-120 min. Peak secretion was nine (0.25% physostigmine), 13 (0.5% physostigmine) and 40 (1% physostigmine) times higher than baseline. At 1% physostigmine, the secretion from the control side was elevated, and a small flow from the duct-cannulated parotid gland occurred, indicating systemic effects. Arterial blood pressure was well maintained. Additional observations on the duct-cannulated zygomatic gland showed that secretion from this gland increased already within the 10-min period of application of physostigmine to the overlying mucosa. The distance between the mucosa and the zygomatic gland was only about 1 mm. Physostigmine-induced secretion was abolished by atropine. Local gland stimulation may be an attractive alternative for the treatment of dry mouth.
Authors:
Jörgen Ekström; Herbert F Helander
Related Documents :
15787629 - Renal-portal shunt ameliorates renovascular hypertension in pigs.
3710429 - Hemodynamic studies in long- and short-term portal hypertensive rats: the relation to s...
8063559 - Effect of gastro-esophageal decongestion on variceal pressure in patients with schistos...
16219059 - Automatic feedback control of relative blood volume changes during hemodialysis improve...
1297679 - Should the jt rather than the qt interval be used to detect prolongation of ventricular...
147639 - Gas embolism death after laparoscopy delayed by "trapping" in portal circulation.
16630359 - Arterial blood pressure monitoring in overweight critically ill patients: invasive or n...
7799109 - Pathophysiology and end-organ damage in elderly hypertensives.
16171479 - Foetal response to music and voice.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  European journal of oral sciences     Volume:  110     ISSN:  0909-8836     ISO Abbreviation:  Eur. J. Oral Sci.     Publication Date:  2002 Jun 
Date Detail:
Created Date:  2002-07-17     Completed Date:  2002-09-06     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  9504563     Medline TA:  Eur J Oral Sci     Country:  Denmark    
Other Details:
Languages:  eng     Pagination:  230-6     Citation Subset:  D; IM    
Affiliation:
Department of Pharmacology, Institute of Physiology and Pharmacology, Göteborg, Sweden. jorgen.ekstrom@pharm.gu.se
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Administration, Buccal
Animals
Atropine / pharmacology
Blood Pressure / drug effects
Cholinesterase Inhibitors / administration & dosage,  pharmacology*
Female
Ferrets
Ganglionic Blockers / pharmacology
Hexamethonium / pharmacology
Lip / drug effects
Models, Animal
Mouth Mucosa / drug effects
Muscarinic Antagonists / pharmacology
Neurotransmitter Agents / pharmacology
Parotid Gland / secretion
Physostigmine / administration & dosage,  antagonists & inhibitors,  pharmacology
Salivary Glands, Minor / drug effects*,  pathology,  secretion
Secretory Rate / drug effects
Statistics as Topic
Submandibular Gland / secretion
Substance P / pharmacology
Time Factors
Vehicles
Chemical
Reg. No./Substance:
0/Cholinesterase Inhibitors; 0/Ganglionic Blockers; 0/Muscarinic Antagonists; 0/Neurotransmitter Agents; 0/Vehicles; 33507-63-0/Substance P; 51-55-8/Atropine; 57-47-6/Physostigmine; 60-26-4/Hexamethonium

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Influence of secondary colonizers and human plasma on the adherence of Porphyromonas gingivalis in v...
Next Document:  Immunohistochemical study on pulpal response in rat molars after cavity preparation by Er:YAG laser.